Banque Cantonale Vaudoise Sells 80,282 Shares of Pfizer Inc. (NYSE:PFE)

Banque Cantonale Vaudoise lowered its holdings in Pfizer Inc. (NYSE:PFE) by 17.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 385,284 shares of the biopharmaceutical company’s stock after selling 80,282 shares during the period. Banque Cantonale Vaudoise’s holdings in Pfizer were worth $11,150,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Olistico Wealth LLC bought a new stake in Pfizer in the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $29,000. Gladius Capital Management LP boosted its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter valued at $31,000. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $24.88 on Tuesday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a 50-day moving average price of $28.55 and a 200-day moving average price of $28.65. The firm has a market cap of $140.97 billion, a PE ratio of 33.62, a P/E/G ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.17) earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.75%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.